Patricia C Valery1,2, Mathieu Laversanne3, Paul J Clark1,2,4,5, Jessica L Petrick6, Katherine A McGlynn6, Freddie Bray3. 1. Population Health, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia. 2. School of Medicine, University of Queensland, Herston, QLD, Australia. 3. Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France. 4. Department of Gastroenterology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia. 5. Department of Gastroenterology, Mater Hospital, South Brisbane, QLD, Australia. 6. Division of Cancer Epidemiology & Genetics, National Cancer Institute, Bethesda, MD, USA.
Abstract
Primary liver cancer (PLC) is the sixth most common cancer worldwide and the second most common cause of cancer death. Future predictions can inform health planners and raise awareness of the need for cancer control action. We predicted the future burden of PLC in 30 countries around 2030. Incident cases of PLC (International Classification of Diseases, Tenth Revision, C22) were obtained from 30 countries for 1993-2007. We projected new PLC cases to 2030 using age-period-cohort models (NORDPRED software). Age-standardized incidence rates per 100,000 person-years were calculated by country and sex. Increases in new cases and rates of PLC are projected in both sexes. The largest increases in rates are, among men, in Norway (2.9% per annum), US whites (2.6%), and Canada (2.4%) and, among women, in the United States (blacks 4.0%), Switzerland (3.4%), and Germany (3.0%). The projected declines are in China, Japan, Singapore, and parts of Europe (e.g., Estonia, Czech Republic, Slovakia). A 35% increase in the number of new cases annually is expected compared to 2005. This increasing burden reflects both increasing rates (and the underlying prevalence of risk factors) and demographic changes. Japan is the only country with a predicted decline in the net number of cases and annual rates by 2030. Conclusion: Our reporting of a projected increase in PLC incidence to 2030 in 30 countries serves as a baseline for anticipated declines in the longer term through the control of hepatitis B virus and hepatitis C virus infections by vaccination and treatment; however, the prospect that rising levels of obesity and its metabolic complications may lead to an increased risk of PLC that potentially offsets these gains is a concern. (Hepatology 2018;67:600-611).
Primary liver cancer (PLC) is the sixth most common cancer worldwide and the second most common cause of cancer death. Future predictions can inform health planners and raise awareness of the need for cancer control action. We predicted the future burden of PLC in 30 countries around 2030. Incident cases of PLC (International Classification of Diseases, Tenth Revision, C22) were obtained from 30 countries for 1993-2007. We projected new PLC cases to 2030 using age-period-cohort models (NORDPRED software). Age-standardized incidence rates per 100,000 person-years were calculated by country and sex. Increases in new cases and rates of PLC are projected in both sexes. The largest increases in rates are, among men, in Norway (2.9% per annum), US whites (2.6%), and Canada (2.4%) and, among women, in the United States (blacks 4.0%), Switzerland (3.4%), and Germany (3.0%). The projected declines are in China, Japan, Singapore, and parts of Europe (e.g., Estonia, Czech Republic, Slovakia). A 35% increase in the number of new cases annually is expected compared to 2005. This increasing burden reflects both increasing rates (and the underlying prevalence of risk factors) and demographic changes. Japan is the only country with a predicted decline in the net number of cases and annual rates by 2030. Conclusion: Our reporting of a projected increase in PLC incidence to 2030 in 30 countries serves as a baseline for anticipated declines in the longer term through the control of hepatitis B virus and hepatitis C virus infections by vaccination and treatment; however, the prospect that rising levels of obesity and its metabolic complications may lead to an increased risk of PLC that potentially offsets these gains is a concern. (Hepatology 2018;67:600-611).
Authors: Fabio Conti; Federica Buonfiglioli; Alessandra Scuteri; Cristina Crespi; Luigi Bolondi; Paolo Caraceni; Francesco Giuseppe Foschi; Marco Lenzi; Giuseppe Mazzella; Gabriella Verucchi; Pietro Andreone; Stefano Brillanti Journal: J Hepatol Date: 2016-06-24 Impact factor: 25.083
Authors: Madlen Schütze; Heiner Boeing; Tobias Pischon; Jürgen Rehm; Tara Kehoe; Gerrit Gmel; Anja Olsen; Anne M Tjønneland; Christina C Dahm; Kim Overvad; Françoise Clavel-Chapelon; Marie-Christine Boutron-Ruault; Antonia Trichopoulou; Vasiliki Benetou; Dimosthenis Zylis; Rudolf Kaaks; Sabine Rohrmann; Domenico Palli; Franco Berrino; Rosario Tumino; Paolo Vineis; Laudina Rodríguez; Antonio Agudo; María-José Sánchez; Miren Dorronsoro; Maria-Dolores Chirlaque; Aurelio Barricarte; Petra H Peeters; Carla H van Gils; Kay-Tee Khaw; Nick Wareham; Naomi E Allen; Timothy J Key; Paolo Boffetta; Nadia Slimani; Mazda Jenab; Dora Romaguera; Petra A Wark; Elio Riboli; Manuela M Bergmann Journal: BMJ Date: 2011-04-07
Authors: Jake E Thistle; Jessica L Petrick; Baiyu Yang; Marie C Bradley; Barry I Graubard; Katherine A McGlynn Journal: Cancer Epidemiol Date: 2018-07-06 Impact factor: 2.984
Authors: Sang Min Yoon; Baek-Yeol Ryoo; So Jung Lee; Jong Hoon Kim; Ji Hoon Shin; Ji Hyun An; Han Chu Lee; Young-Suk Lim Journal: JAMA Oncol Date: 2018-05-01 Impact factor: 31.777
Authors: Dorothy A Rhoades; John Farley; Stephen M Schwartz; Kimberly M Malloy; Wenyu Wang; Lyle G Best; Ying Zhang; Tauqeer Ali; Fawn Yeh; Everett R Rhoades; Elisa Lee; Barbara V Howard Journal: Cancer Epidemiol Date: 2021-07-19 Impact factor: 2.890